Anti Inflammatory News and Research

RSS

Eat 'heart-healthy' oats to prevent atherosclerosis

Nutritionist Mohsen Meydani, director of the Vascular Biology Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University in Boston, Mass., led the research on the oat compounds, called avenanthramides. Meydani previously has shown that phenolic antioxidants in oats obstruct the ability of blood cells to stick to artery walls.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Use of non-steroidal anti-inflammatory drugs not associated with risk of squamous cell skin cancer

Contrary to previous hypotheses, the use of non-steroidal anti-inflammatory drugs does not appear associated with risk of squamous cell skin cancer, according to a report posted online today that will appear in the April print issue of Archives of Dermatology, one of the JAMA/Archives journals.

16 Feb 2010

People can take simple steps to minimize risk of exposure to allergens during gardening, AAAAI

The beauty of budding plants and bouquet of aromas are sources of satisfaction for many gardeners. For allergy sufferers, though, gardening can be as much a chore as pursuit of passion.

15 Feb 2010

Bacterin International completes $3M private placement of Secured Convertible Promissory Notes

Bacterin International, Inc. (Bacterin), a developer of biological scaffolds for orthopedic indications, today announced the completion of a $3 million private placement of Secured Convertible Promissory Notes led by Middlebury Securities, LLC.

14 Feb 2010

Cyanotech announces fiscal 2010 third quarter results

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the third quarter and first nine months of fiscal 2010, ended December 31, 2009.

12 Feb 2010

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Glissandra Skincare™ Inc., dedicated to the research, development, and manufacturing of anti-aging skincare products, announced it has signed its first distributorship agreement granting Enchanted Meadow the rights to distribute Glissandra to its more than 2000 spa and gift industry retailers throughout the US and Canada.

10 Feb 2010

Doctors do not follow evidence-based guidelines for treating low back pain, says report

Australian general practitioners often treat patients with low back pain in a manner that does not appear to match the care endorsed by international clinical guidelines, according to a report in the February 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Feb 2010

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.

9 Feb 2010

BioElectronics and SAY-GIN sign agreement to sell ActiPatch and Allay products in Turkey

BioElectronics Corp., the maker of inexpensive, disposable, drug-free anti-inflammatory devices, today announced it has reached an agreement with SAY-GIN Ozel Egtim Yayincilik Ticaret Hizmetleri (SAY-GIN) for distribution of its ActiPatch and Allay products in Turkey.

9 Feb 2010

Reliv International adds new products to its portfolio

Reliv International, Inc. introduced three new products to its Relivables line at the company's national conference here today. The products represent the first extension of the Relivables line since it was introduced last August.

6 Feb 2010

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Fast growing Scottish biotech company Sistemic Ltd today announced that it had closed a series A funding round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund. The company will use the funding to further develop its proprietary SistemRNA compound-centric drug discovery technology. Using SistemRNA shortens the odds in drug discovery by enabling far more accurate prediction of potential drug indications, interactions and side effects.

4 Feb 2010

Anti-inflammatory plant derivative could play a role in cancer treatment, say MCG researchers

Medical College of Georgia researchers are seeking to refine cancer treatment with an anti-inflammatory plant derivative long used in Chinese medicine.

4 Feb 2010

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.

2 Feb 2010

Safer bone marrow transplants

If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.

2 Feb 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

Anacor Pharmaceuticals announced today that it will present a poster and oral presentation on a novel systemic anti-inflammatory candidate, AN6415, at the upcoming 8th Cytokines and Inflammation Conference, taking place January 28-29, 2010 in La Jolla, California.

28 Jan 2010

Research suggests pomegranate seed extract could stimulate uterine contractions

The team identified beta-sitosterol - a steroid that can inhibit the absorption of cholesterol in the intestine - as the main constituent of pomegranate seed extract. The research suggests that pomegranate extract could be used as a natural stimulant to encourage the uterus to contract during labour.

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

Anti Inflammatory News and Research

Eat 'heart-healthy' oats to prevent atherosclerosis

Meda publishes 2009 year-end report

Use of non-steroidal anti-inflammatory drugs not associated with risk of squamous cell skin cancer

People can take simple steps to minimize risk of exposure to allergens during gardening, AAAAI

Bacterin International completes $3M private placement of Secured Convertible Promissory Notes

Cyanotech announces fiscal 2010 third quarter results

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Doctors do not follow evidence-based guidelines for treating low back pain, says report

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

BioElectronics and SAY-GIN sign agreement to sell ActiPatch and Allay products in Turkey

Reliv International adds new products to its portfolio

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Anti-inflammatory plant derivative could play a role in cancer treatment, say MCG researchers

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Safer bone marrow transplants

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Celgene reports total revenue of $758M for fourth-quarter of 2009

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

Research suggests pomegranate seed extract could stimulate uterine contractions

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News